Company News

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA for locally advanced or metastatic EGFR-mutant NSCLC

Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) were presented at 2024 CSCO Congress.

Positive results from multiple studies of Kelun Biotech's TROP2 ADC (Sac-TMT) in advanced solid tumors were presented at 2024 ESMO Congress.

Three study abstracts for sac-TMT (TROP2 ADC) to be presented at 2024 ESMO Congress.

Klus Pharma to attend ESMO Congress 2024 in Barcelona, Spain from Sept 13-17, 2024.

Klus Pharma to attend ADC & Radiopharmaceuticals Pharma and Biotech Partnering Summit in Boston, MA from Sept 9-10, 2024.

Klus Pharma to attend 15th Annual World ADC in San Diego from November 4-7th, 2024.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA

Two abstracts of SKB264/sac-TMT (TROP2 ADC) were published at 2024 ASCO Annual Meeting to be held in Chicago from May 31 to June 4.

Kelun-Biotech and Ellipses A400 (EP0031) Cleared to Start Ph2 Clinical Development by US FDA

KLUS Pharma will attend 2024 BIO International Convention held in San Diego from June 3-6.

Kelun-Biotech will present the results from two clinical studies of SKB264/sac-TMT at the 2024 AACR Annual Meeting.